Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning

Inclusion Criteria

• •Participants must have histologically confirmed prostate cancer.
• •PSA level and prostate biopsy must be reviewed at Brigham and Women's Hospital or the Dana Farber Cancer Institute and should support a diagnosis of stage I-III prostate adenocarcinoma.
• •Candidates with PSA greater than 20, digital rectal exam consistent with disease outside the prostate (clinical T3/T4 disease), or Gleason score 8 or greater, should have a bone scan and diagnostic pelvic CT or MRI to exclude metastatic disease.
• •Prostate biopsy, serum PSA measurement, and any indicated diagnostic imaging studies must be performed within 60 days of the date of registration.
• •Participants should not have had prior curative local treatment for prostate cancer, including no radiotherapy or prostatectomy. A maximum 90 days of systemic androgen deprivation therapy prior to registration is allowed.
• •Participation is limited to adult patients, age 18 years or older.
• •ECOG performance status ≥2 (Karnofsky ≥60%)
• •Life expectancy of greater than 10 years.
• •Able to tolerate an MRI examination.
• •Ability to understand and the willingness to sign a written informed consent document.